初始eGFR与白蛋白尿变化对接受SGLT2抑制剂治疗的糖尿病患者临床结局的影响
基于台湾多中心数据库8222例2型糖尿病患者,分析启动SGLT2抑制剂后3个月eGFR和UACR早期变化与临床结局的关联。eGFR下降>10%且UACR无降低者,MARE、MACE及HHF/心血管死亡风险显著升高。提示该亚组需更密切监测。
要点
- eGFR下降>10%且UACR无降低者MARE风险aHR 2.34(95%CI 1.32-4.15)。
- 该组MACE风险aHR 1.83(95%CI 1.01-3.29),HHF/心血管死亡aHR 1.93(95%CI 1.05-3.55)。
- 作者认为此类患者需更密切监测并可能采用更积极治疗策略。
核心结论
- 2型糖尿病患者接受SGLT2抑制剂治疗早期出现eGFR大幅下降且UACR未同步降低,代表临床结局更差的高危亚组。
- 作者认为该人群需要更密切监测并可能采用更积极的治疗策略。
研究设计与样本
- 利用台湾大型多中心医疗数据库,分析2016年6月1日至2021年12月31日期间接受SGLT2抑制剂的8222例2型糖尿病患者,均有基线和3个月随访的eGFR及UACR测量。
- 采用Cox比例风险模型评估主要不良肾脏事件(MARE)、主要不良心血管事件(MACE)、心力衰竭住院(HHF)和全因死亡风险。
主要发现
- 治疗3个月后按eGFR早期变化(无下降、0%-10%下降、>10%下降)和UACR变化(无降低、0%-30%降低、>30%降低)分组。
- eGFR无下降者占40.9%,其中UACR无降低者19.8%、0%-30%降低者8.4%、>30%降低者12.7%。
- eGFR下降>10%者占21.5%,其中UACR无降低者6.5%、0%-30%降低者4.3%、>30%降低者10.7%。
- 与eGFR轻度早期下降且UACR降低者相比,eGFR下降>10%且UACR无降低者MARE风险aHR 2.34(95%CI 1.32-4.15)、MACE风险aHR 1.83(95%CI 1.01-3.29)、HHF/心血管死亡风险aHR 1.93(95%CI 1.05-3.55)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为对eGFR大幅下降且UACR未同步降低的2型糖尿病接受SGLT2抑制剂治疗患者,需更密切监测并可能采用更积极治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The relationship between initial changes in estimated glomerular filtration rate (eGFR) and urine albumin to creatinine ratio (UACR), and their independent association with clinical outcomes in type 2 diabetes (T2D) patients receiving sodium-glucose cotransporter 2 inhibitors (SGLT2is), remains unclear. OBJECTIVE: This study aimed to investigate the association between initial changes in eGFR and UACR with consequent cardiovascular and kidney outcomes in an Asian population with T2D following SGLT2i treatment in a real-world setting. METHODS: Using a large multicenter medical database in Taiwan, we analyzed 8222 T2D patients with baseline and 3-month follow-up eGFR and UACR measurements, receiving SGLT2is between June 1, 2016, and December 31, 2021. We assessed risks of major adverse renal events (MARE), major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and all-cause mortality using a Cox proportional hazards model. RESULTS: After 3 months of SGLT2i treatment, patients were categorized based on early changes in eGFR (no decline, 0%-10% decline, > 10% decline) and UACR (no reduction, 0%-30% reduction, > 30% reduction). Among those with no initial eGFR decline (40.9%), 19.8% had no initial UACR reduction, 8.4% had 0% to 30% reduction, and 12.7% had greater than 30% reduction. For those with greater than 10% initial eGFR decline (21.5%), 6.5% had no UACR reduction, 4.3% had 0% to 30% reduction, and 10.7% had greater than 30% reduction. Patients with greater than 10% initial eGFR decline but no UACR reduction showed higher risks of MARE (adjusted HR [aHR]: 2.34; 95% CI, 1.32-4.15), MACE (aHR: 1.83; 95% CI, 1.01-3.29), and HHF/cardiovascular death (aHR: 1.93; 95% CI, 1.05-3.55) compared to those with modest early eGFR decline and UACR reduction. CONCLUSION: T2D patients experiencing profound early eGFR decline without concordant UACR reduction while on SGLT2is represent a high-risk subgroup with worse clinical outcomes. These findings suggest the need for closer monitoring and potentially more aggressive therapeutic strategies for this patient population.
引用
- Huang B, Kao YW, Yen KC, et al. Effect of Initial eGFR and Albuminuria Changes on Clinical Outcomes in People With Diabetes Receiving SGLT2 Inhibitors. J Clin Endocrinol Metab. 2025. PMID: 40171668. doi:10.1210/clinem/dgaf133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。